在阿片类药物治疗计划中用甲治疗Kratom使用障碍
1Chief Science Officer, Community Medical Services (RCS).
Journal of addiction medicine
|February 12, 2026
概括
甲有效治疗了卡拉使用障碍 (KUD),表现出良好的耐受性和保留率. 这项研究支持将甲作为KUD管理的可行选择,当布普伦诺芬不适合时.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 毒理学 毒理学 毒理学
背景情况:
- 克拉 (Mitragyna speciosa) 和其类化合物可以引起类似阿片类药物的依赖和戒断,符合阿片类药物使用障碍 (OUD) 的标准.
- 虽然布普伦诺芬已被记录在Kratom使用障碍 (KUD) 中,但对甲的临床经验很少.
研究的目的:
- 评估甲在治疗KUD患者中的疗效和安全性.
- 评估KUD患者队列中甲的耐受性和保留率.
主要方法:
- 在多个阿片类药物治疗计划 (OTP) 中,对14名KUD患者进行了以甲治疗的回顾性评估.
- 对人口统计,甲剂量和尿液毒理学数据的分析.
- 研究期:2024年1月至2025年10月.
主要成果:
- 该研究包括14名患者,平均年龄为36.8岁,71%是男性.
- 64%的人报告说,他们同时使用了kratom和7-hydroxymitragynine (7-OH).
- 平均初始甲剂量为27.5毫克,平均最大剂量为98.6毫克. 93%的患者继续接受治疗,没有报告任何不良事件.
结论:
- 甲被很好地容忍,并且有效地稳定了KUD患者.
- 甲代表了KUD的可行的治疗选择,特别是当布普伦诺芬不适合时.
相关概念视频
Treatment Strategies for Psychological Disorders
797
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
797
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.1K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.1K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
976
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
976


